Subcutaneous Expansion Target biopharma developers with IV biologics seeking subcutaneous options, leveraging AcousticaBio to broaden delivery options, align with patient demand, and unlock new value across pipelines.

Conversion Enablement The platform enables converting existing biologics into very high concentration small volume injections without solvents or post-processing, reducing manufacturing steps and accelerating timelines for injectable programs.

Platform Versatility Platform versatility enables application across multiple modalities, supporting adoption across a partner's entire portfolio and creating cross-sell opportunities.

Manufacturing Efficiency Improved manufacturability and streamlined logistics help reduce fill-finish bottlenecks and simplify distribution for injectable biologics, enhancing overall supply chain efficiency for pharma partners.

IP and Partnerships An IP backed differentiator leveraging Harvard patented acoustophoretic technology opens doors for co development or licensing deals, shortening sales cycles and distinguishing AcousticaBio from competitors.